PT  - JOURNAL ARTICLE
AU  - Navarro, Cristian Eduardo
AU  - Betancur, John Edison
AU  - Porras-Ramírez, Alexandra
TI  - Cost-utility analysis comparing ocrelizumab vs rituximab in the treatment of relapsing-remitting multiple sclerosis: The Colombian perspective
AID  - 10.1101/2022.08.23.22279145
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.23.22279145
4099  - http://medrxiv.org/content/early/2022/08/24/2022.08.23.22279145.short
4100  - http://medrxiv.org/content/early/2022/08/24/2022.08.23.22279145.full
AB  - Introduction Since 2017, the ocrelizumab is available to treat patients with relapsing-remitting multiple sclerosis (RRMS), together with rituximab, they have a similar effectiveness but different costs. In this context, the added value provided by cost-effectiveness estimators for decision-making and drug prescription can be considered.Objective to determine the cost-utility of ocrelizumab versus rituximab in patients with RRMS, from the perspective of the Colombian health system.Methodology cost-utility study based on a Markov model, with a 50-year horizon and payer perspective. The currency was the US Dollar (USD) for the year 2019, with a threshold of $5,180 USD defined for Colombian health system. The model used annual cycles according to the health status determined by the disability scale. Direct costs were considered, and the incremental cost-effectiveness ratio (ICER) per 1 quality-adjusted life year (QALY) gained was used as the outcome measure. A discount rate of 5% was applied for costs and outcomes. Multiple one-way deterministic sensitivity analyzes and 10,000 modeling through Monte Carlo simulation were performed.Results for the treatment of patients with RRMS, ocrelizumab versus rituximab had an ICER of $73,652 USD for each QALY gained. After 50 years, 1 subject treated with ocrelizumab earns 4.8 QALYs more than 1 subject treated with rituximab, but at a higher cost of $521,759 USD vs $168,752 USD, respectively. Ocrelizumab becomes a cost-effective therapy when its price is discounted >86%, or there is a high willingness to pay.Conclusions Ocrelizumab was not a cost-effective drug compared with rituximab to treat patients with RRMS in Colombia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript